View clinical trials related to Lymphoma, Non-Hodgkins.
Filter by:Background: -Cluster of differentiation 19 (CD19) and cluster of differentiation 20 (CD20) are often found on certain cancer cells. Researchers think that a person's T cells can be modified in a lab to kill cells that have CD19 and CD20 on the surface. Objective: -To see if it is safe to give anti-CD19 and anti-CD20 CAR T cells to people with a B cell cancer or Hodgkin lymphoma. Eligibility: -People ages 18 and older with a B cell cancer or Hodgkin lymphoma that has not been controlled with standard therapies Design: - Participants will be screened under protocol 01C0129 with: - Medical history - Physical exam - Blood and heart tests - Bone marrow biopsy: A needle is inserted into the participant's hip bone to remove a small amount of marrow. Scans - Participants will have apheresis: Blood will be removed through a vein. The blood with circulate through a machine that removes the T cells. The rest of the blood will be returned to the participant. - Once a day for 3 days before they get the T cells, participants will receive chemotherapy through a vein. - Participants will receive the T cells through a vein. They will stay in the hospital for at least 9 days. - Participants may have a lumbar puncture: A needle will remove fluid from the spinal cord. - Participants may have a tumor biopsy. - Participants will repeat the screening tests throughout the study. - Participants will have follow-up visits 2 weeks after infusion; monthly for 4 months; at 6, 9, and 12 months; every 6 months for 3 years; and then annually for 5 years. Participants will then be contacted annually for 15 years.
The purpose of this study is to: Investigate the Overall Response Rate (ORR) of the combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin lymphoma (LG-NHL) that relapse beyond 6 months of a previous rituximab-containing regimen.